Michael Rader

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

Karim Fizazi, Michael A. Carducci, Matthew R. Smith et al. · The Lancet · 2011 · 2K citations · Full text

Medicine, Oncology, Urology +17

Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma.

Scott Wadler, Edward L. Schwartz, Marc Goldman et al. · Journal of Clinical Oncology · 1989 · 328 citations

Pharmacy, Oncology, Pharmacotherapy +15

Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer

Karim Fizazi, Christophe Massard, Matthew R. Smith et al. · European Urology · 2014 · 143 citations

Medicine, Oncology, Urology +16

Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States

Alison Stopeck, Michael Rader, David Henry et al. · Journal of Medical Economics · 2012 · 70 citations

Pharmacy, Oncology, Pharmacoeconomics +17

Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: A prospective, multicenter, open-label, randomized, two-way crossover drug—drug interaction study

Karthik Venkatakrishnan, Michael Rader, Ramesh K. Ramanathan et al. · Clinical Therapeutics · 2009 · 62 citations

Medicine, Pharmacokinetics, Pharmacology +6